Chronic noninfectious uveitis associated with Vogt–Koyanagi–Harada disease treated with low-dose weekly systemic methotrexate

@article{Kondo2011ChronicNU,
  title={Chronic noninfectious uveitis associated with Vogt–Koyanagi–Harada disease treated with low-dose weekly systemic methotrexate},
  author={Yukiko Kondo and Ken I. Fukuda and Katsuyoshi Suzuki and Teruo Nishida},
  journal={Japanese Journal of Ophthalmology},
  year={2011},
  volume={56},
  pages={104-106}
}
Methotrexate (MTX) is a highly effective and safe nonsteroidal immunosuppressant used for the daily treatment of systemic inflammatory diseases, for example rheumatoid arthritis [1] and juvenile idiopathic arthritis [2]. MTX has also been found to be effective in the treatment of uveitis [3–5], but it has adverse effects that may necessitate its withdrawal. We describe three cases of chronic uveitis associated with Vogt–Koyanagi–Harada disease (VKH) that were treated by low-dose, weekly… CONTINUE READING